Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard®

MADISON, Wis., & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement to co-promote Exact Sciences' Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. The agreement provides for the near-term expansion of Cologuard promotional efforts through the use of Ironwood's clinical sales specialists to more than double the number of physicians reached in the United States. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.

Read More

Topics: Exact Sciences News

Exact Sciences and Mayo Clinic Extend, Expand Collaboration to Continue Fighting Cancer through Advanced Screening

Unique Arrangement Aims to Build on the Success of Cologuard®

MADISON, Wis. -- Exact Sciences Corp. (NASDAQ: EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.

Read More

Topics: Exact Sciences News

Exact Sciences Announces Norton Healthcare to Adopt Cologuard

First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure.

Read More

Topics: Investor Relations